Document is current
Any future updates will be listed below
-
Authors
Lee, Bei Shi
Hards, Kiel
Engelhart, Curtis A
Hasenoehrl, Erik J https://orcid.org/0000-0002-1507-741X
Kalia, Nitin P
Mackenzie, Jared S https://orcid.org/0000-0002-3089-0900
Sviriaeva, Ekaterina
Chong, Shi Min Sherilyn
Manimekalai, Malathy Sony S
Koh, Vanessa H
Chan, John
Xu, Jiayong
Alonso, Sylvie
Miller, Marvin J
Steyn, Adrie J C
Grüber, Gerhard
Schnappinger, Dirk
Berney, Michael
Cook, Gregory M
Moraski, Garrett C
Pethe, Kevin https://orcid.org/0000-0003-0916-8873
-
Funding
Funding for this research was provided by:
MOH | National Medical Research Council (NMRC/CBRG/0083/2015)
National Research Foundation Singapore (NRF‐CRP18‐2017‐01)
Nanyang Technological University
HHS | National Institutes of Health (R01 AI139465)
HHS | National Institutes of Health (F30 AI138483)
HHS | National Institutes of Health (R37 AI054193)
HHS | National Institutes of Health (R01 AI137043)
Potts Memorial foundation
Nanyang Technological University
Royal Society of New Zealand
Manatu Hauora | Health Research Council of New Zealand
South African Medical Research Council
- License Information
-
More Information
Article History
Received: 4 August 2020
Revised: 28 October 2020
Accepted: 30 October 2020
First Online: 7 December 2020
Conflict of interest
: M. J. M., G. C. M., and K. P. are named as inventors on a patent application related to this work: patent #WO2020128981, “Discovery of bd oxidase inhibitors for the treatment of mycobacterial diseases”. Hsiri Therapeutics has licensed this technology. M. J. M. and G. C. M. own equity in Hsiri Therapeutics. M. J. M. is an employee of Hsiri therapeutics. G. C. M. and K. P. are consultants to Hsiri therapeutics. Hsiri Therapeutics did not fund this study and was not involved in study design or interpretation.
